MARKET

MNOV

MNOV

Medicinova
NASDAQ
1.250
0.000
0.00%
After Hours: 1.250 0 0.00% 16:04 07/07 EDT
OPEN
1.250
PREV CLOSE
1.250
HIGH
1.310
LOW
1.250
VOLUME
20.37K
TURNOVER
--
52 WEEK HIGH
2.550
52 WEEK LOW
1.120
MARKET CAP
61.31M
P/E (TTM)
-5.4921
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MNOV last week (0630-0704)?
Weekly Report · 19h ago
Weekly Report: what happened at MNOV last week (0623-0627)?
Weekly Report · 06/30 10:31
Weekly Report: what happened at MNOV last week (0616-0620)?
Weekly Report · 06/23 10:26
Medicinova Announces Results of Annual Stockholders Meeting
TipRanks · 06/18 21:06
MediciNova Is Maintained at Buy by B. Riley Securities
Dow Jones · 06/16 17:45
MediciNova Price Target Cut to $5.00/Share From $6.00 by B. Riley Securities
Dow Jones · 06/16 17:45
B. Riley Securities Maintains Buy on MediciNova, Lowers Price Target to $5
Benzinga · 06/16 17:34
MediciNova price target lowered to $5 from $6 at B. Riley
TipRanks · 06/16 13:20
More
About MNOV
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.

Webull offers Medicinova Inc stock information, including NASDAQ: MNOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNOV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNOV stock methods without spending real money on the virtual paper trading platform.